Latest Upsher-Smith Laboratories Inc. Stories
<font size="2" face="Arial"> </font> MAPLE GROVE, Minn., Dec. 5, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced the presentation of Phase 1 data showing that once-daily administration of USL255, a proprietary, extended-release (ER) formulation of the epilepsy medication topiramate, demonstrated linear dose-proportionality and, when compared to immediate-release (IR) topiramate administered twice-daily, an improved...
MAPLE GROVE, Minn., Dec. 2, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced plans to launch its new epilepsy-focused educational website, www.Epilog.us, at the American Epilepsy Society (AES) annual meeting, December 3-5, 2011. The new website will be featured at the Upsher-Smith booth (# 102) and marks an important landmark in the Company's commitment to the epilepsy community. To view the multimedia assets associated with this...
AUSTIN, Texas, Oct. 13, 2011 /PRNewswire/ -- The National Association of Nurse Practitioners in Women's Health (NPWH) today revealed data from a national survey of approximately 900 nurse practitioners that explored external factors that impact the type of estrogen therapy (ET) that is prescribed for symptoms associated with menopause. Studies suggest that transdermal ET may have the potential for fewer health risks and that it controls symptoms of menopause as effectively as oral ET,(1-7)...
MAPLE GROVE, Minn., Sept. 26, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced the presentation of Phase I data showing that once daily administration of USL255, a proprietary extended-release (ER) formulation of the epilepsy medication topiramate, demonstrated equivalent topiramate exposure to immediate-release (IR) topiramate dosed twice daily. These findings were presented Monday, September 26, at the American Neurological Association's...
MAPLE GROVE, Minn., Sept. 26, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. is proud to support the National Eczema Association (NEA) during Eczema Awareness Month to raise awareness about this disease and the resources available to help those who suffer from eczema. For eligible patients, Upsher-Smith offers a "pay no more than $15" coupon for Trianex((TM) )0.05% (Triamcinolone Acetonide Ointment), a prescription corticosteroid with the feel of a cream and strength of an ointment...
MAPLE GROVE, Minn., Sept. 7, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., maker of the AmLactin® family of moisturizers, announced today the launch of the AmLactin® Facebook page, making it easy for dry skin sufferers to unite and share their stories. To show our appreciation, fans who join the AmLactin® Facebook community will receive a $3 coupon for any AmLactin® Moisturizing Body Lotion or Cream. (Logo: http://photos.prnewswire.com/prnh/20100923/MM70018-a) "We want...
MAPLE GROVE, Minn., Aug. 1, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. announced today that it received the prestigious AmerisourceBergen Manufacturer of the Year Award for branded pharmaceutical sales under $500 million at the annual National Healthcare Conference and Exposition (NHCE) in Las Vegas, NV held July 19-23, 2011. NHCE is one of the largest conferences of its kind, bringing together community pharmacy leaders, pharmaceutical manufacturers, health and beauty aids...
MAPLE GROVE, Minn., July 25, 2011 /PRNewswire/ -- In a comparative pharmacokinetic (PK) study, Upsher-Smith Laboratories' USL255, a new, once-daily extended-release formulation of topiramate in development for the management of epilepsy in adults, was shown to be bioequivalent to twice-daily immediate-release topiramate (Topamax®*) in its extent of absorption. Furthermore, USL255, administered with or without food, demonstrated a slower absorption profile compared with Topamax®. The...
MAPLE GROVE, Minn., July 18, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for...
MAPLE GROVE, Minn., July 11, 2011 /PRNewswire/ -- Today Upsher-Smith Laboratories, Inc. announced the launch of Trianex(TM) 0.05% (Triamcinolone Acetonide Ointment), a prescription topical corticosteroid offering the feel of a cream with the strength of an ointment. Trianex(TM) combines triamcinolone, the No. 1 prescribed type of topical corticosteroid,(1) with a pleasing cream-like base to relieve inflammation and itching in skin conditions that respond to treatment with corticosteroids,...
